Market Cap 36.15M
Revenue (ttm) 30,000.00
Net Income (ttm) -14.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -47,633.33%
Debt to Equity Ratio 0.00
Volume 179,800
Avg Vol 214,934
Day's Range N/A - N/A
Shares Out 50.05M
Stochastic %K 12%
Beta 0.56
Analysts Strong Sell
Price Target $3.25

Company Profile

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral,...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 650 216 3500
Address:
1850 Gateway Drive, Suite 175, San Mateo, United States
Noname2022
Noname2022 Apr. 2 at 5:47 PM
$CRMD $TLPH $FMS Niyad! Can’t help but thinking Cormedix relationships with FMS along with FMS interest in the CRRT space have got to be positives…
0 · Reply
firedupinvestors
firedupinvestors Mar. 31 at 11:18 AM
0 · Reply
Yoda896
Yoda896 Mar. 29 at 11:45 PM
$TLPH Nafamostat may be expensive/unavailable outside Asia now because there is no demand for it right now. But, once Niyad is approved, it will be manufactured and made available at a lower cost than Citrate. Shakil Aslam - 2026/03/23 CC - 0:54:47: "Nafamostat is not gonna be more expensive than citrate."
1 · Reply
nazzangr
nazzangr Mar. 29 at 8:14 PM
$TLPH looks like this is from the conference held this weekends. Looks at the pros and cons lol cons basically only have “expensive” https://kdigo.org/wp-content/uploads/2026/03/KDIGO-2026-AKI-AKD-Guideline-Public-Review-Draft-March-2026.pdf
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Mar. 26 at 2:00 AM
$TLPH CEO purchased 213,310 shares at $0.59 for a total of $125,000. Angotti Vincent J. now owns 800,705 shares. https://ceo-buys.com
0 · Reply
nazzangr
nazzangr Mar. 25 at 12:36 PM
$TLPH things are moving lets go
0 · Reply
iLiealot
iLiealot Mar. 25 at 10:49 AM
$TLPH Another call? nice
1 · Reply
Yoda896
Yoda896 Mar. 24 at 9:07 PM
$TLPH Vincent Angotti - March 23, 2026 CC (Location 0:02:28) "As of December 31st, we had cash and investments of $20.4 million, which, along with the remaining tranches, if closed, should provide runway through a potential FDA approval of Niyad next year." Notice he said "if closed" Since they were not closed yet, and as usual, the deal would be for the institutional investors to commit to spend $4.1 million (or more?) at the closing price of a certain day. So, if the day in question is today, as a think it must be, the buyers would try to close the stock at a low price. This way they get more shares for $4.1 million. If I'm right, the stock should start going up tomorrow, and go over $1 very quickly. You said you wanted a dumbass answer. So, there you go ;)
1 · Reply
Crandaddy01
Crandaddy01 Mar. 24 at 8:37 PM
0 · Reply
BigTpain
BigTpain Mar. 24 at 7:31 PM
$TLPH somebody explain to me in dumbass terms please. We had a good invester call. The volume is great today yet it moves the wrong direction?
2 · Reply
Latest News on TLPH
CorMedix Announces Strategic Minority Investment in Talphera

Sep 8, 2025, 8:30 AM EDT - 7 months ago

CorMedix Announces Strategic Minority Investment in Talphera

CRMD


Talphera to Participate at A.G.P. Virtual Healthcare Conference

May 16, 2024, 5:45 PM EDT - 2 years ago

Talphera to Participate at A.G.P. Virtual Healthcare Conference


Noname2022
Noname2022 Apr. 2 at 5:47 PM
$CRMD $TLPH $FMS Niyad! Can’t help but thinking Cormedix relationships with FMS along with FMS interest in the CRRT space have got to be positives…
0 · Reply
firedupinvestors
firedupinvestors Mar. 31 at 11:18 AM
0 · Reply
Yoda896
Yoda896 Mar. 29 at 11:45 PM
$TLPH Nafamostat may be expensive/unavailable outside Asia now because there is no demand for it right now. But, once Niyad is approved, it will be manufactured and made available at a lower cost than Citrate. Shakil Aslam - 2026/03/23 CC - 0:54:47: "Nafamostat is not gonna be more expensive than citrate."
1 · Reply
nazzangr
nazzangr Mar. 29 at 8:14 PM
$TLPH looks like this is from the conference held this weekends. Looks at the pros and cons lol cons basically only have “expensive” https://kdigo.org/wp-content/uploads/2026/03/KDIGO-2026-AKI-AKD-Guideline-Public-Review-Draft-March-2026.pdf
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Mar. 26 at 2:00 AM
$TLPH CEO purchased 213,310 shares at $0.59 for a total of $125,000. Angotti Vincent J. now owns 800,705 shares. https://ceo-buys.com
0 · Reply
nazzangr
nazzangr Mar. 25 at 12:36 PM
$TLPH things are moving lets go
0 · Reply
iLiealot
iLiealot Mar. 25 at 10:49 AM
$TLPH Another call? nice
1 · Reply
Yoda896
Yoda896 Mar. 24 at 9:07 PM
$TLPH Vincent Angotti - March 23, 2026 CC (Location 0:02:28) "As of December 31st, we had cash and investments of $20.4 million, which, along with the remaining tranches, if closed, should provide runway through a potential FDA approval of Niyad next year." Notice he said "if closed" Since they were not closed yet, and as usual, the deal would be for the institutional investors to commit to spend $4.1 million (or more?) at the closing price of a certain day. So, if the day in question is today, as a think it must be, the buyers would try to close the stock at a low price. This way they get more shares for $4.1 million. If I'm right, the stock should start going up tomorrow, and go over $1 very quickly. You said you wanted a dumbass answer. So, there you go ;)
1 · Reply
Crandaddy01
Crandaddy01 Mar. 24 at 8:37 PM
0 · Reply
BigTpain
BigTpain Mar. 24 at 7:31 PM
$TLPH somebody explain to me in dumbass terms please. We had a good invester call. The volume is great today yet it moves the wrong direction?
2 · Reply
prismmarketview
prismmarketview Mar. 24 at 3:38 PM
$TLPH talphera just hit 50% enrollment in its Phase 3 kidney replacement therapy study. All 12 sites are active. A PMA filing is targeted for end of 2026. Analysts see a potential approval pathway in mid-2027. https://prismmarketview.com/talphera-reaches-phase-3-milestone-in-kidney-replacement-therapy/
0 · Reply
RunningRobert1
RunningRobert1 Mar. 24 at 12:54 PM
$TLPH Talphera TLPH 2026 Summary 24Mar2026 https://youtu.be/8tpbj0vp3UI So data is coming soon, enrollment seems to be picking up, and we have money until data. All of these things are fairly bullish, the big bearish parts of the warrants that will prob be cashed after data, but that seems like a after data problem, so lets enjoy the runup!
0 · Reply
Bitchisback
Bitchisback Mar. 24 at 5:42 AM
$TLPH I had a parent who was on dialysis and they could sit there for hrs waiting for their blood to clot.. I have been invested in this stock since June of 2023 in honor of them. If this gets approved it will be life changing for so many people.. I hope it 🚀 but I also hope it works and gets approved because it will be life changing for so many people.. For the people betting against this, I hope YOU or a family member never have to experience life on dialysis…
0 · Reply
Estimize
Estimize Mar. 24 at 12:03 AM
$TLPH reported -0.06 EPS and 0.00 revenue for Q4. http://www.estimize.com/intro/tlph?chart=historical&metric_name=eps&utm_content=TLPH&utm_
0 · Reply
Scipio88
Scipio88 Mar. 23 at 8:09 PM
$TLPH @RunningRobert1 How soon Cuz i got margin called and what are you thinking target price wise?
1 · Reply
Brunoez
Brunoez Mar. 23 at 8:05 PM
$TLPH One last note for today: It's discouraging that the market didn't react favorably to the outstanding investor call this morning. However, Niyad is a superior product with a proven track record. Our day will come.
0 · Reply
Crestpontoon
Crestpontoon Mar. 23 at 8:03 PM
0 · Reply
Brunoez
Brunoez Mar. 23 at 7:23 PM
$TLPH One important point made during the call regarding future adoption: The lady doctor stated that in many cases, doctors choose to use no anticoagulant at all due to the risks associated with heparin. As such, the potential market for Niyad will be larger than the set of patients who are currently receiving anticoagulants. She also envisioned usage outside of the CRRT arena.
0 · Reply
Yoda896
Yoda896 Mar. 23 at 7:19 PM
$TLPH CEO said at location 1:06, quoted word for word: "The reason it slipped past first half of the year was because two sites that we were planning on having just continued to delay. It wasn't anything to do with us or the contracts, and it was their own internal issues. And one in particular had all research studies on hold while they were revamping their research protocols throughout their facility. And they just recently released the ability to initiate studies again, and we were one of the first couple that were initiated, and they lifted the hold, and immediately activated the study with the training refresh..." Vincent and Dr. Aslam talked about this at a few different spots. I got the impression that Dr. Aslam expects conclusion shortly after mid-year because of the pickup in pace. He gave the woman doctor as an example. He mentioned that she enrolled 3 people just last week. You owe it to yourself to listen to it carefully. Turn Closed Captions on. They're very good.
1 · Reply
SteveHardWood
SteveHardWood Mar. 23 at 6:22 PM
0 · Reply
RunningRobert1
RunningRobert1 Mar. 23 at 6:11 PM
$TLPH I like it, data coming soon!
0 · Reply
Acemaker12
Acemaker12 Mar. 23 at 6:07 PM
$TLPH Excellent investor call this morning. Physicians on the call did an outstanding job describing the challenges they face with existing options for anticoagulation during dialysis in the ICU. I thought their insights were very interesting.
0 · Reply